Opinion|Videos|August 8, 2024
Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL
Medical experts specializing in acute lymphoblastic leukemia explore emerging trends and potential future developments for CAR T-cell therapy in treating relapsed or refractory B-cell ALL.
Advertisement
Video content above is prompted by the following:
- What are future directions for CAR T-cell therapy in r/r B-Cell ALL?
- What unmet needs still exist in the treatment paradigm of r/r B-cell ALL?
- Can each of you share any key takeaways or additional data updates that you would like to highlight surrounding r/r B-cell ALL presented at EHA 2024? (if time permits)
Advertisement
Related to this article
Peter Voorhees, MD, discusses the integration of CAR T-cell therapy in early-relapsed myeloma and the importance of early T-cell–redirecting therapy use.
Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.
The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.
SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.
Cathy Eng, MD, FACP, FASCO, discusses how oncology fellows can navigate the journal submission and review process.
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
4
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
5